Advertisement
LLY vs ZTS
Which Stock Would AI Choose? Eli Lilly and Company (LLY) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- LLY shares have declined about 5-8% in recent weeks amid broader market corrections, despite strong Q4 earnings and robust 2026 guidance driven by Mounjaro and Zepbound.
- ZTS has faced pressure with a 1-year drop of around 27-29%, influenced by analyst downgrades and growth concerns, though it reported solid Q4 results and acquired Neogen's genomics business.
- Both stocks operate in healthcare but differ in focus: LLY in human pharmaceuticals with high growth potential, ZTS in animal health with stable but slower expansion.
- LLY trades at a higher PE ratio (around 43x) reflecting premium growth expectations, while ZTS at about 20x appears more attractively valued.
- Recent momentum favors neither decisively, with YTD performance mixed: LLY down ~8%, ZTS down ~3%.
- Tickeron's AI tools highlight sector rotations, potentially benefiting pharma and animal health plays in volatile conditions.
Introduction
Eli Lilly and Company (LLY) and Zoetis Inc. (ZTS) represent distinct segments within the healthcare sector, with LLY leading in human therapeutics like diabetes and obesity treatments, and ZTS dominating animal health for companion and livestock products. This stock comparison is relevant for investors seeking exposure to healthcare growth drivers amid market volatility, including those balancing high-momentum pharma plays against resilient niche markets. Traders analyzing relative performance, sector exposure, and recent catalysts will find insights into positioning for short-term trends or long-term stability in this essential industry.
LLY Overview and Recent Performance
Eli Lilly and Company (LLY), a global pharmaceutical giant, specializes in innovative treatments for diabetes, obesity, oncology, and immunology. Its blockbuster drugs Mounjaro and Zepbound have fueled revenue growth, with recent quarterly earnings exceeding expectations and 2026 projections signaling continued expansion around 25% in sales. In recent market activity, LLY shares have pulled back 5-8% from post-earnings peaks, trading near $990 amid broader equity corrections and pricing pressures in the obesity market. Sentiment reflects caution over competition and valuation after a multi-year rally, yet strong fundamentals like 31% profit margins and analyst targets above $1,200 support rebound potential. Key influences include partnerships expanding access to its therapies and robust demand projections.
ZTS Overview and Recent Performance
Zoetis Inc. (ZTS), the world's leading animal health company, develops vaccines, medicines, and diagnostics for companion animals and livestock. Recent quarters showed steady revenue growth around 4% organically, with Q4 adjusted EPS beating estimates and 2026 guidance for $9.8-10B in sales. Shares have declined 4-5% in recent weeks, hovering near $121, extending a 27-29% 1-year drop due to growth outlook concerns, analyst downgrades, and divestitures of mature products. Positive developments include a $160M acquisition of Neogen's genomics business to bolster precision animal health. Sentiment is tempered by competition in key portfolios like Librela, but operational efficiency with 72% gross margins and a dividend yield near 1.75% provide stability.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of over 25 high-performing AI trading bots from its library of hundreds, each trained on thousands of tickers across stocks, ETFs, and crypto. These bots are dynamically ranked based on real-time adaptability to market conditions like volatility and sector rotations, featuring stats such as annualized returns up to +218%, win rates of 70-95%, profit factors from 1.6 to 25+, and average trade durations spanning 1 day to 62 days. Strategies vary from short-term swing trading on 5-60 minute timeframes to trend-following in sectors like biotech and infrastructure, with low drawdowns (under $2,000 in top performers) and high profit-to-drawdown ratios exceeding 20. Explore these bots to enhance your trading edge in dynamic environments.
Head-to-Head Comparison
LLY and ZTS both benefit from healthcare tailwinds but diverge in business models: LLY's human pharma focus drives explosive growth via blockbuster GLP-1 drugs, contrasting ZTS's defensive animal health niche with steady demand from pet ownership and livestock needs. Growth drivers for LLY include obesity market expansion, while ZTS leverages acquisitions like Neogen for genomics innovation. Recent momentum shows both underperforming short-term, but LLY boasts superior YTD and multi-year gains versus ZTS's sharper declines. Risk factors differ: LLY faces patent cliffs and competition, ZTS regulatory hurdles in vet meds; ZTS offers lower beta (0.95 vs. 0.43) for stability. Market sentiment tilts toward LLY's catalysts despite premium valuation, while ZTS trades at a discount with analyst upside to $152.
Tickeron AI Verdict
Tickeron's AI currently leans toward LLY based on stronger trend consistency in growth sectors, superior revenue catalysts from obesity drugs, and relative positioning post-earnings. While ZTS provides attractive valuation and stability, LLY's higher projected EPS growth and market momentum suggest a probabilistic edge in the near term, particularly amid healthcare rotations observable in AI bot performances.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Hold and ZTS is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 2 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).
- LLY’s FA Score: 2 green, 3 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 5 TA indicator(s) are bullish while ZTS’s TA Score has 5 bullish TA indicator(s).
- LLY’s TA Score: 5 bullish, 3 bearish.
- ZTS’s TA Score: 5 bullish, 4 bearish.
Price Growth
LLY (@Pharmaceuticals: Major) experienced а -1.32% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was +3.84% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.70%. For the same industry, the average monthly price growth was +8.17%, and the average quarterly price growth was +2.15%.
Reported Earning Dates
LLY is expected to report earnings on Apr 30, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Pharmaceuticals: Generic (+3.70% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| LLY | ZTS | LLY / ZTS | |
| Capitalization | 828B | 51.5B | 1,608% |
| EBITDA | 31.7B | 4.07B | 779% |
| Gain YTD | -13.595 | -2.319 | 586% |
| P/E Ratio | 40.39 | 20.33 | 199% |
| Revenue | 65.2B | 9.47B | 689% |
| Total Cash | 7.27B | 2.31B | 315% |
| Total Debt | 42.5B | 9.24B | 460% |
LLY | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 20 | 100 | |
SMR RATING 1..100 | 13 | 16 | |
PRICE GROWTH RATING 1..100 | 55 | 60 | |
P/E GROWTH RATING 1..100 | 94 | 85 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (30) in the Pharmaceuticals Generic industry is in the same range as LLY (62) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (20) in the Pharmaceuticals Major industry is significantly better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that LLY’s stock grew significantly faster than ZTS’s over the last 12 months.
LLY's SMR Rating (13) in the Pharmaceuticals Major industry is in the same range as ZTS (16) in the Pharmaceuticals Generic industry. This means that LLY’s stock grew similarly to ZTS’s over the last 12 months.
LLY's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as ZTS (60) in the Pharmaceuticals Generic industry. This means that LLY’s stock grew similarly to ZTS’s over the last 12 months.
ZTS's P/E Growth Rating (85) in the Pharmaceuticals Generic industry is in the same range as LLY (94) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to LLY’s over the last 12 months.
| LLY | ZTS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 74% | 4 days ago 52% |
| Stochastic ODDS (%) | 3 days ago 70% | 3 days ago 62% |
| Momentum ODDS (%) | 3 days ago 61% | 3 days ago 61% |
| MACD ODDS (%) | 3 days ago 67% | 3 days ago 65% |
| TrendWeek ODDS (%) | 3 days ago 59% | 3 days ago 56% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 54% |
| Advances ODDS (%) | 11 days ago 71% | 6 days ago 52% |
| Declines ODDS (%) | 4 days ago 55% | 4 days ago 58% |
| BollingerBands ODDS (%) | 3 days ago 81% | 3 days ago 62% |
| Aroon ODDS (%) | 3 days ago 57% | 3 days ago 61% |
Advertisement
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +2.81% | ||
| ELAN - ZTS | 46% Loosely correlated | +2.38% | ||
| PRGO - ZTS | 38% Loosely correlated | +3.33% | ||
| VTRS - ZTS | 37% Loosely correlated | +4.78% | ||
| HLN - ZTS | 37% Loosely correlated | +1.67% | ||
| PAHC - ZTS | 36% Loosely correlated | +5.92% | ||
More | ||||